Teva Pharmaceutical Industries (TEVA) closed at $42.23 on November 18, 2026, down 0.9% from the previous close, on volume of 7,080,204 shares (30-day average 7,175,993).
Data as of November 18, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 26, 2026 | Calendar Call Ladder | 18-Dec-2642 C|15-Jan-2744 : 49 C | 6,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 18, 2026. See the largest for 5, 30, 60 and 90 days
Barclays Sticks to Their Buy Rating for Teva (TEVA)
TipRanks (Thu, 19-Nov 5:06 AM ET)
Teva Announces R&D Chief Departure and Transition Leadership
TipRanks (Wed, 18-Nov 5:43 PM ET)
Teva Announces R&D Leadership Transition; Eric Hughes to Depart the Company
Globe Newswire (Wed, 18-Nov 5:00 PM ET)
Teva’s Igalmi Home-Use FDA Clearance Supports Buy Rating and $54 Price Target
TipRanks (Wed, 18-Nov 4:55 AM ET)
Glenview ups stakes in Meta, Teva; cuts CVS, Block in Q3; exits DKS, STM
Seeking Alpha News (Tue, 17-Nov 5:18 AM ET)
Einhorn's DME exits PayPal, Stubhub, adds Century Aluminum, among Q3 moves
Seeking Alpha News (Mon, 16-Nov 6:46 PM ET)
Teva Stock Slips as the Drugmaker Reaches a Settlement Agreement in a Price-Fixing Lawsuit
TipRanks (Mon, 16-Nov 12:48 PM ET)
Teva gains at-home indication for Igalmi for agitation with schizophrenia
Seeking Alpha News (Mon, 16-Nov 12:36 PM ET)
Globe Newswire (Mon, 16-Nov 8:00 AM ET)
Globe Newswire (Wed, 11-Nov 7:30 AM ET)
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Teva Pharmaceutical Industries trades on the NYSE stock market under the symbol TEVA.
As of November 19, 2026, TEVA stock price declined to $39.96 with 3,510,431 million shares trading.
TEVA has a beta of 1.11, meaning it tends to be more sensitive to market movements. TEVA has a correlation of 0.15 to the broad based SPY ETF.
TEVA has a market cap of $46.61 billion. This is considered a Large Cap stock.
Last quarter Teva Pharmaceutical Industries reported $4 billion in Revenue and $.86 earnings per share. This beat revenue expectation by $146 million and exceeded earnings estimates by $.14.
In the last 3 years, TEVA traded as high as $44.57 and as low as $9.04.
The top ETF exchange traded funds that TEVA belongs to (by Net Assets): IEFA, EFA, EIS, IXUS, EFG.
TEVA has outperformed the market in the last year with a price return of +60.9% while the SPY ETF gained +11.9%. TEVA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +9.2% and -4.5%, respectively, while the SPY returned -4.5% and -4.7%, respectively.
TEVA support price is $41.35 and resistance is $43.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TEVA shares will trade within this expected range on the day.